Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2116 to 2130 of 2548 results for methods

  1. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    In development Reference number: GID-TA10895 Expected publication date:  29 October 2026

    Technology appraisal guidance
    In development

  2. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued Reference number: GID-TAG410

    Technology appraisal guidance
    Discontinued

  3. VEST external stent for coronary artery bypass grafts (MIB115)

    NICE has developed a medtech innovation briefing (MIB) on the VEST external stent for coronary artery bypass grafts .

    Medtech innovation briefing
    Published
    2 August 2017

  4. Service user experience in adult mental health services (QS14)

    This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    31 July 2019
    View quality statements

    Sections for QS14

  5. Suture fixation of acute disruption of the distal tibiofibular syndesmosis (IPG521)

    Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.

    Interventional procedures guidance
    Published
    26 June 2015
    View recommendations

    Sections for IPG521

  6. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    In development Reference number: GID-HST10020 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  7. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

    Technology appraisal guidance
    Discontinued

  8. Lasmiditan for treating acute migraine [ID3759]

    Discontinued Reference number: GID-TA10807

    Technology appraisal guidance
    Discontinued

  9. Benralizumab for previously treated severe nasal polyps [ID1659]

    In development Reference number: GID-TA10818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    Discontinued Reference number: GID-TA10841

    Technology appraisal guidance
    Discontinued

  11. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development Reference number: GID-TA11146 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

    Technology appraisal guidance
    Discontinued

  13. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued Reference number: GID-TAG415

    Technology appraisal guidance
    Discontinued

  14. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued Reference number: GID-TA10185

    Technology appraisal guidance
    Discontinued

  15. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued Reference number: GID-TAG444

    Technology appraisal guidance
    Discontinued